Competitive inhibition: 50-100 times stronger binding affinity to CD4 T cells than HIV.
Neutralizes all HIV clades and subtypes regardless tropism, as well as HIV strains resistant to antiretrovirals, broadly neutralizing antibodies, CCR5 receptor antagonists, or ibalizumab.
Inhibits both cell-to-cell and cell-free transmission of HIV.
Modulates immune responses: Treg% and PD-1% reduction and CD8 expansion.
Reduces HIV reservoir